[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. (XERS) Form 4 discloses insider reporting by Kevin McCulloch, President and Chief Operating Officer. On September 11, 2025 Mr. McCulloch, acting as trustee of the Charles R. McCulloch Trust, caused the trust to distribute 2,000 shares of Xeris common stock to a trust beneficiary; the Form notes no sale occurred in the transfer. The filing reports Mr. McCulloch's beneficial ownership following the transaction as 1,701,159 shares and an indirect holding of 25,000 shares attributable to his spouse. The reporting person disclaims beneficial ownership of distributed shares except to the extent of pecuniary interest.

Insights

Financial Analyst

TL;DR: Trustee distribution of 2,000 shares by an officer is a routine intra-family transfer and appears immaterial to XERS ownership.

The filing documents a trustee-initiated distribution rather than a market sale, which does not change outstanding share count or reflect a disposition in the open market. The report clarifies beneficial ownership totals: 1,701,159 shares directly/beneficially owned by the reporting person and 25,000 indirectly via spouse. For investors, this is a disclosure of internal ownership movements with no indicated change to company operations or capital structure.

Corporate Governance Expert

TL;DR: The Form 4 correctly discloses an internal trust distribution and includes a beneficial ownership disclaimer; it raises no governance red flags.

The report identifies the reporter's role as President and COO and discloses the trustee relationship and distribution mechanics. The explanatory remarks properly disclaim beneficial ownership of distributed shares except for pecuniary interest, which aligns with Section 16 reporting norms. Signature by attorney-in-fact is included. No omitted or ambiguous transaction details are evident in the filing text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		J(1)		2,000	D	$0	0	I	By Charles R. McCulloch Trust dated 1990
Common Stock								1,701,159	D
Common Stock								25,000(2)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is trustee of the Charles R. McCulloch Trust, of which he is a beneficiary. On September 11, 2025, the reporting person caused the trust to distribute 2,000 shares of the Issuer's common stock to a beneficiary of the trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. No sale of shares occurred in the transfer.

2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Kevin McCulloch report on Form 4 for XERS?

The Form 4 reports that on 09/11/2025 the trustee (Charles R. McCulloch Trust) distributed 2,000 shares of Xeris common stock to a trust beneficiary; no sale occurred.

How many XERS shares does Kevin McCulloch beneficially own after the reported transaction?

The filing reports 1,701,159 shares beneficially owned following the reported transaction.

Does the Form 4 show any derivative transactions for XERS by the reporting person?

No. The Form 4 contains no entries in Table II for derivative securities; only a non-derivative distribution is reported.

Is there any indication the reported shares were sold on the open market?

No. The explanatory note states no sale of shares occurred in the transfer; it was a trust distribution to a beneficiary.

What relationship to Xeris does the reporting person have?

The filing identifies Kevin McCulloch as an Officer (President and Chief Operating Officer) and reports holdings held directly and indirectly (spouse).